---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-308382"
form_type: "8-K"
ticker: "KLRS"
cik: "0001754068"
company_name: "Kalaris Therapeutics, Inc."
filed_at: "2026-07-20T12:07:21+00:00"
generated_at: "2026-07-20T12:10:08.158192+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Kalaris appoints Liisa Bayko as CFO; CAO Brett Hagen resigns

## Summary
- Liisa Bayko appointed CFO and Treasurer effective July 20, 2026; base salary $475,000, target bonus 40%, option for 220,000 shares.
- Brett Hagen resigns as SVP Finance and Chief Accounting Officer effective July 27, 2026.
- Amy Vandekop, Corporate Controller, designated interim principal accounting officer effective July 27, 2026.
- Bayko's option vests 25% on first anniversary, then monthly over 3 years; severance includes 9-12 months salary depending on change in control.
- Bayko previously Managing Director at Evercore ISI and JMP Securities.

## SEC filing metadata
- accession: 0001193125-26-308382
- form_type: 8-K
- ticker: KLRS
- cik: 0001754068
- company_name: Kalaris Therapeutics, Inc.
- filed_at: 2026-07-20T12:07:21+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1754068/000119312526308382/0001193125-26-308382-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1754068/000119312526308382/d125092d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-308382
- JSON: https://secwatch.observer/filing/0001193125-26-308382.json
- Plain text: https://secwatch.observer/filing/0001193125-26-308382.txt

## Key facts
- Executive change
  Liisa Bayko was appointed as Chief Financial Officer and Treasurer at Kalaris Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Financial Officer and Treasurer
  source text: On July 16, 2026, the Board of Directors (the “Board”) of Kalaris Therapeutics, Inc. (the “Company”) appointed Liisa Bayko as Chief Financial Officer and Treasurer of the Company, effective as of July 20, 2026 (the “Effective Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1754068/000119312526308382/0001193125-26-308382-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.